Epidermal Growth Factor Receptor (EGFR) sensitizing mutation targeted therapy represents one of the breakthroughs in non-small cell lung cancer (NSCLC) treatment in the new century3. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.